Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1620-1629

  Baig, Nisar A ^a   Taylor, Ronald P ^b   Lindorfer, Margaret A ^b   Church, Amy K ^a   LaPlant, Betsy R ^a   Pettinger, Adam M ^a   Shanafelt, Tait D ^a   Nowakowski, Grzegorz S ^a   Zent, Clive S ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; COMPLEMENT; OFATUMUMAB;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPENDENT CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOCYTE COUNT; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PENTOSTATIN; TREATMENT OUTCOME;

EID: 84896716648     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302954     Document Type: Article

References (53)

1. Keating, M. J., S. O'Brien, M. Albitar, S. Lerner, W. Plunkett, F. Giles, M. Andreeff, J. Cortes, S. Faderl, D. Thomas, et al. 2005. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23: 4079-4088.
2. Kay, N. E., S. M. Geyer, T. G. Call, T. D. Shanafelt, C. S. Zent, D. F. Jelinek, R. Tschumper, N. D. Bone, G. W. Dewald, T. S. Lin, et al. 2007. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109: 405-411.
3. Hallek, M., K. Fischer, G. Fingerle-Rowson, A. M. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, et al International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164-1174.
4. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
5. Zent, C. S., C. R. Secreto, B. R. LaPlant, N. D. Bone, T. G. Call, T. D. Shanafelt, D. F. Jelinek, R. C. Tschumper, and N. E. Kay. 2008. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 32: 1849-1856.
6. Zent, C. S., J. B. Chen, R. C. Kurten, G. P. Kaushal, H. M. Lacy, and S. A. Schichman. 2004. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk. Res. 28: 495-507.
7. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
8. Teeling, J. L., W. J. Mackus, L. J. Wiegman, J. H. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-371.
9. Pawluczkowycz, A. W., F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. van de Winkel, P. W. Parren, and R. P. Taylor. 2009. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183: 749-758.
10. Bologna, L., E. Gotti, F. Da Roit, T. Intermesoli, A. Rambaldi, M. Introna, and J. Golay. 2013. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 190: 231-239.
11. Beurskens, F. J., M. A. Lindorfer, M. Farooqui, P. V. Beum, P. Engelberts, W. J. Mackus, P. W. Parren, A. Wiestner, and R. P. Taylor. 2012. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 188: 3532-3541.
12. Wierda, W. G., T. J. Kipps, J. Mayer, S. Stilgenbauer, C. D. Williams, A. Hellmann, T. Robak, R. R. Furman, P. Hillmen, M. Trneny, et al; Hx-CD20-406 Study Investigators. 2010. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28: 1749-1755.
13. Wierda, W. G., S. Padmanabhan, G. W. Chan, I. V. Gupta, S. Lisby, and A. Osterborg; Hx-CD20-406 Study Investigators. 2011. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118: 5126-5129.
14. Coiffier, B., S. Lepretre, L. M. Pedersen, O. Gadeberg, H. Fredriksen, M. H. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, et al. 2008. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111: 1094-1100.
15. Wierda, W. G., T. J. Kipps, J. Dürig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F. J. Hernandez-Ilizaliturri, et al; 407 Study Investigators. 2011. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117: 6450-6458.
16. Shanafelt, T., M. C. Lanasa, T. G. Call, A. W. Beaven, J. F. Leis, B. LaPlant, D. Bowen, M. Conte, D. F. Jelinek, C. A. Hanson, et al. 2013. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 119: 3788-3796.
17. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288.
18. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609.
19. Beers, S. A., R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
20. Beum, P. V., E. M. Peek, M. A. Lindorfer, F. J. Beurskens, P. J. Engelberts, P. W. Parren, J. G. van de Winkel, and R. P. Taylor. 2011. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 187: 3438-3447.
21. Lim, S. H., A. T. Vaughan, M. Ashton-Key, E. L. Williams, S. V. Dixon, H. T. Chan, S. A. Beers, R. R. French, K. L. Cox, A. J. Davies, et al. 2011. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118: 2530-2540.
22. Boross, P., J. H. Jansen, A. Pastula, C. E. van der Poel, and J. H. Leusen. 2012. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol. Lett. 143: 44-52.
23. Daubeuf, S., M. A. Lindorfer, R. P. Taylor, E. Joly, and D. Hudrisier. 2010. The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J. Immunol. 184: 1897-1908.
24. Baig, N. A., R. P. Taylor, M. A. Lindorfer, A. K. Church, B. R. Laplant, E. S. Pavey, G. S. Nowakowski, and C. S. Zent. 2012. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk. Lymphoma 53: 2218-2227.
25. Hallek, M., B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Döhner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, and T. J. Kipps; International Workshop on Chronic Lymphocytic Leukemia. 2008. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
26. Morice, W. G., P. J. Kurtin, J. M. Hodnefield, T. D. Shanafelt, J. D. Hoyer, E. D. Remstein, and C. A. Hanson. 2008. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin. Proc. 83: 776-785.
27. Döhner, H., S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger, K. Döhner, M. Bentz, and P. Lichter. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343: 1910-1916.
28. Dewald, G. W., S. R. Brockman, S. F. Paternoster, N. D. Bone, J. R. O'Fallon, C. Allmer, C. D. James, D. F. Jelinek, R. C. Tschumper, C. A. Hanson, et al. 2003. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 121: 287-295.
29. Jelinek, D. F., R. C. Tschumper, S. M. Geyer, N. D. Bone, G. W. Dewald, C. A. Hanson, M. J. Stenson, T. E. Witzig, A. Tefferi, and N. E. Kay. 2001. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haematol. 115: 854-861.
30. Rassenti, L. Z., L. Huynh, T. L. Toy, L. Chen, M. J. Keating, J. G. Gribben, D. S. Neuberg, I. W. Flinn, K. R. Rai, J. C. Byrd, et al. 2004. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351: 893-901.
31. Beum, P. V., A. D. Kennedy, and R. P. Taylor. 2004. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289: 97-109.
32. Rossmann, E. D., R. Lenkei, J. Lundin, H. Mellstedt, and A. Osterborg. 2007. Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin. Cytom. 72: 450-457.
33. Brando, B., W. Göhde, Jr., B. Scarpati, and G. G. D'Avanzo; European Working Group on Clinical Cell Analysis. 2001. The "vanishing counting bead" phenomenon: effect on absolute CD34+ cell counting in phosphate-buffered salinediluted leukapheresis samples. Cytometry 43: 154-160.
34. Lindorfer, M. A., H. B. Jinivizian, P. L. Foley, A. D. Kennedy, M. D. Solga, and R. P. Taylor. 2003. B cell complement receptor 2 transfer reaction. J. Immunol. 170: 3671-3678.
35. Harris, C. L., D. M. Lublin, and B. P. Morgan. 2002. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J. Immunol. Methods 268: 245-258.
36. Bleeker, W. K., M. E. Munk, W. J. Mackus, J. H. van den Brakel, M. Pluyter, M. J. Glennie, J. G. van de Winkel, and P. W. Parren. 2008. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140: 303-312.
37. Hu, W., X. Ge, T. You, T. Xu, J. Zhang, G. Wu, Z. Peng, M. Chorev, B. H. Aktas, J. A. Halperin, et al. 2011. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 71: 2298-2307.
38. Williams, M. E., J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor. 2006. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 177: 7435-7443.
39. Curtis, J. E., E. M. Hersh, and E. J. Freireich. 1972. Leukapheresis therapy of chronic lymphocytic leukemia. Blood 39: 163-175.
40. Cooper, I. A., J. C. Ding, P. B. Adams, M. A. Quinn, andM. Brettell. 1979. Intensive leukapheresis in the management of cytopenias in patients with chronic lymphocytic leukaemia (CLL) and lymphocytic lymphoma. Am. J. Hematol. 6: 387-398.
41. Huh, Y. O., M. J. Keating, H. L. Saffer, I. Jilani, S. Lerner, and M. Albitar. 2001. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am. J. Clin. Pathol. 116: 437-443.
42. Tam, C. S., J. Otero-Palacios, L. V. Abruzzo, J. L. Jorgensen, A. Ferrajoli, W. G. Wierda, S. Lerner, S. O'Brien, and M. J. Keating. 2008. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br. J. Haematol. 141: 36-40.
43. Lindorfer, M. A., A. Wiestner, C. S. Zent, and R. P. Taylor. 2012. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? OncoImmunology 1: 959-961.
44. Rossi, E. A., D. M. Goldenberg, R. Michel, D. L. Rossi, D. J. Wallace, and C. H. Chang. 2013. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood 122: 3020-3029.
45. Taylor, R. P. 2013. Gnawing at Metchnikoff's paradigm. Blood 122: 2922-2924.
46. Schreiber, A. D., and M. M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51: 575-582.
47. Schreiber, A. D., and M. M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J. Clin. Invest. 51: 583-589.
48. Kabbash, L., J. Esdaile, S. Shenker, F. Decary, D. Danoff, A. Fuks, and J. Shuster. 1987. Reticuloendothelial system Fc receptor function in systemic lupus erythematosus: effect of decreased sensitization on clearance of autologous erythrocytes. J. Rheumatol. 14: 487-489.
49. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826.
50. Lindorfer, M. A., J. Koehl, and R. P. Taylor. 2013. Interactions between the complement system and Fcg receptors. In IgG Fc: Linking Adaptive and Innate Immunity. F. Nimmerhahn, and M. Ackerman, eds. Elsevier, New York, NY, p. 49-69.
51. Batista, F. D., D. Iber, and M. S. Neuberger. 2001. B cells acquire antigen from target cells after synapse formation. Nature 411: 489-494.
52. Harshyne, L. A., S. C. Watkins, A. Gambotto, and S. M. Barratt-Boyes. 2001. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J. Immunol. 166: 3717-3723.
53. Smyth, L. A., N. Harker, W. Turnbull, H. El-Doueik, L. Klavinskis, D. Kioussis, G. Lombardi, and R. Lechler. 2008. The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type. J. Immunol. 181: 3212-3220.